N-Acetyl Cysteine (NAC) for Viral Load Reduction
NAC supports glutathione status without affecting viral replication.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 600-1200mg/day
- Expected timeframe
- 8-12 weeks
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient. Interest arose because glutathione depletion is well documented in HIV infection, and in vitro work showed NAC could inhibit NF-kB-driven HIV replication in cell culture. Human trials at 600-1,800 mg/day did show restoration of glutathione and improvements in some immune markers, but they did not demonstrate reductions in plasma HIV viral load. The same pattern holds for other viral infections - hepatitis, influenza, SARS-CoV-2 - where NAC has been examined for oxidative stress, mucolysis or inflammatory outcomes rather than viral replication, and where trials have not shown meaningful reductions in viral load. NAC modifies host redox state; it does not interfere with viral replication machinery the way antiviral drugs do.
- titration
- Not applicable
- starting dose
- Not applicable - NAC is not an antiviral
Evidence
What the studies say
No studies are yet linked to both N-Acetyl Cysteine (NAC) and Viral Load Reduction.
Safety
Caveats
No antiviral effect. May interact with nitroglycerin.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.